Conchinobio released on April 29, 2024 its unaudited first quarter report for the three months ended March 31, 2024. The report showed that the company's operating income was RMB 1.14 billion, an increase of 13.65% year-on-year. However, the company had a net loss attributable to shareholders of listed companies of RMB 1.7 billion and basic earnings per share of negative $0.69. R&D investments totaled RMB 1.24 billion and accounted for 108.79% of operating income, down 41.25 percentage points from the same period last year. The company's total assets were RMB85.69 billion, down 8.05% year-on-year. In the quarter, the company's total assets and total liabilities decreased, resulting in an investment loss of approximately RMB 7051 million, as the drug was no longer included in the merger scope...Show More

Conchinobio released on April 29, 2024 its unaudited first quarter report for the three months ended March 31, 2024. The report showed that the company's operating income was RMB 1.14 billion, an increase of 13.65% year-on-year. However, the company had a net loss attributable to shareholders of listed companies of RMB 1.7 billion and basic earnings per share of negative $0.69. R&D investments totaled RMB 1.24 billion and accounted for 108.79% of operating income, down 41.25 percentage points from the same period last year. The company's total assets were RMB85.69 billion, down 8.05% year-on-year. In the quarter, the company's total assets and total liabilities decreased, resulting in an investment loss of approximately RMB 7051 million, as the drug was no longer included in the merger scope. In addition, in March 2024, the company received litigation materials submitted to a Brazilian court, involving a claim for compensation of approximately 1,67 billion reais (approximately RMB2.41 million), and the company has hired a team of professional lawyers to handle the lawsuit. The total number of ordinary shareholders at the end of the reporting period was 21,770.